塞普特纳生物

关于 Septerna

Septerna, Inc. is a clinical-stage biotechnology company, which 从事 pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was 成立 by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is 总部位于 in South San Francisco, CA.

成立时间

2019

首席执行官

Dr. Jeffrey T. Finer, M.D.,PhD

员工人数

130

总部地址

South San Francisco, California, United States of America

财年结束日

12-31

官方网站

septerna.com

公司概况

交易所

US

股票代码

SEPN

市值排名

#2886

上市日期

2024-10-25

市值

1.70B

流通市值

832.28M

总股数

46.68M

流通股数

22.90M

行业与主题板块

浏览全部行业与主题板块